|
|
|
|
|
HONG KONG, June 11, 2009 - (ACN Newswire) - The Board of Mingyuan Medicare Development Company Limited ("Mingyuan Medicare" or the "Company", Stock code: 0233) is pleased to announce today that the Company had entered into a milestone co-operation agreement (the "Co-operation Agreement") with Chinese National Human Genome Centre in Shanghai ("CHGC") and Shanghai Biochip Company Limited ("SBC") on the joint establishment of an uniquely dynamic technology platform with rapid response capability to develop diagnostic kits for early detection of major or new infectious diseases on demand basis. The platform is important for the industrialization of high-tech national medical products. All parties to the Co-operation Agreement have successfully developed two advanced diagnostic kits for detecting Influenza A viruses, namely the "Influenza A Virus Genotyping Detection Kit (RNA FQ-PCR)" and the "Influenza A Virus Genotyping Detection Kit (Sequencing)".
The two products above are able to qualitatively detect new Influenza A/H1N1 virus, seasonal Influenza A H1 virus and Non-A H1 Influenza virus and identify with fluorescent labels, being applicable to respiratory tract sample test (nasopharynx swab / aspirate or nasal cavity wash / aspirate). The diagnostic kits are able to detect Influenza A viruses at a very early stage of infection. As the test result is available in 2 hours, the kits can be used in hospitals, border checkpoints and clinics to help diagnose suspected symptomatic and asymptomatic infections and thus effectively prevent the virus from further spreading.
Mr. Henry Chien, CEO of Mingyuan Medicare, said, "We are honoured to be a partner of CHGC and SBC. The technology platform with rapid response capability to develop diagnostic kits for early detection of major or new infectious diseases is believed to play an important role in the development of human health. Currently, Influenza A viruses (including the recent outbreak of Influenza A (H1N1) virus) is a highly infectious disease which has long been regarded as a major health hazard to human. Furthermore, the World Health Organization may soon raise the influenza pandemic alert level from Phase 5 to Phase 6, the highest pandemic phase. The two newly-developed advanced diagnostic kits for detecting Influenza A viruses help to identify Human Swine Flu (A H1N1) patients, and this is believed to be critical to effectively preventing the spread of the infectious disease and to improve the chance of recovery."
The State Council published Certain Policies to Promote Bio-industry Development aiming at building bio industry into pillars of high-tech sector and new strategic sector of China. Many policies such as supporting the development of biomedical sector and preferential taxation will facilitate the industrialization of high-tech medical products and rapid development of the industry. As the leader of the biomedical industry, Mingyuan Medicare is the first to benefit from such supportive policies. At the same time, Mingyuan Medicare has been attracting investment from world-renowned companies such as the strong and prominent CCBI. It has also established mutually beneficial commercial partnership with China Life, the insurance company in China with the largest market share, and GE (China) Co., Ltd. Healthcare, the leader in the healthcare industry. These moves clearly demonstrate the Companys strengths and prospects.
Moreover, the Company recently acquired Genetel BVI as well as 75% equity interest in Shanghai Kang Pei Bio-Medical Company Limited, which further strengthen the Company's DNA technology and products whilst expanding its health check services and network of medical centres.
About Chinese National Human Genome Centre in Shanghai
Chinese National Human Genome Centre in Shanghai (CHGC) is a national research centre established in 1998 for fulfilling the national scientific projects of human genome research and its application and development for China. CHGC was founded by many established institutes from the related biotech fields in Shanghai and the relevant government agencies including the Chinese Ministry of Science and Technology, Shanghai Municipal Government and Chinese Academy of Sciences ("CAS"). Visit www.chgc.sh.cn/en/.
About Shanghai Biochip Company Limited
Founded in 2001, Shanghai Biochip Company Limited ("SBC") is one of the largest biotech companies in China and is also the National Engineering Center for biochip design and engineering in Shanghai. Facilitated with advanced biotech platforms and labs and operated by strong teams for research, services, marketing and sales, SBC provides a series of biochips and related technical services, proprietary drug targets and relevant diagnostic products. SBC is funded by the Chinese government and was founded by eleven shareholders including the Shanghai Institute for Biological Sciences of CAS and other shareholders consisting of all top academic universities, research institutes, hospitals, and leading biotech companies in China. Visit www.shbiochip.com.
Contact:
Wonderful Sky Financial Group Limited
Joanne Chan / Sally Wong / Ally Cheung
Tel: (852) 2851 1038
Fax: (852) 2815 1352
E-mail: joannechan@wsfg.hk / sallywong@wsfg.hk / allycheung@wsfg.hk
Topic: Corporate Announcement
Source: Mingyuan Medicare
Sectors: Health & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
|
